Figures & data
Table 1 Macronutrient intakes
Fig. 1 Between-treatment effects on body composition variables are illustrated in graph (a) Body mass, (b) Body fat mass, (c) Dry lean mass, and (d) Body fat %. Abbreviations: PLA, Placebo; LD, Theacrine Low Dose; HD, Theacrine High Dose. There were no main effects of time, group*time interactions or group*time*gender interactions for select body composition variables
Table 2 Cardiovascular safety markers, part I
Table 3 Cardiovascular safety markers, part II
Table 4 Serum clinical safety markers, part I
Table 5 Serum clinical safety markers, part II
Table 6 Serum clinical safety markers, part III
Table 7 Clinical whole blood safety markers, part I
Table 8 Mood and concentration profiles
